<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534638</url>
  </required_header>
  <id_info>
    <org_study_id>106636</org_study_id>
    <secondary_id>2007-001731-55</secondary_id>
    <nct_id>NCT00534638</nct_id>
  </id_info>
  <brief_title>Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents</brief_title>
  <official_title>Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and
      women. The most important disease associated with oncogenic HPV infection is cervical cancer,
      currently the second leading cause of cancer-related death among women globally. The current
      study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15
      years of age.

      This protocol posting has been updated following protocol amendment 09, 24 March 2014. The
      sections impacted are secondary objectives, endpoints, final analyses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 4, 2007</start_date>
  <completion_date type="Actual">December 17, 2014</completion_date>
  <primary_completion_date type="Actual">December 17, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Female Subjects With Vaccine Overall Effectiveness Against Genital Infection With Human Papilloma Virus (HPV) 16/18 Serotypes</measure>
    <time_frame>At the time of visit 5 (at 18.5 years of age)</time_frame>
    <description>The analysis of overall effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in all subjects from the investigated group (prevalence rate in all subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Female Subjects With Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Serotypes</measure>
    <time_frame>At the time of visit 5 (at 18.5 years of age)</time_frame>
    <description>The analysis of total effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in HPV vaccinated subjects from the investigated group (prevalence rate in HPV vaccinated subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms, in a Subset of Subjects.</measure>
    <time_frame>Within 7 days (Days 0 - 6) after any vaccination</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Solicited General Symptoms, in a Subset of Subjects.</measure>
    <time_frame>Within 7 days (Days 0 - 6) after any vaccination</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms, headache, myalgia, rash and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Unsolicited Adverse Events (AEs), in a Subset of Subjects.</measure>
    <time_frame>Within 30 days (Days 0 - 29) after any vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Rash and Urticaria, in a Subset of Subjects.</measure>
    <time_frame>Within 30 minutes following vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects.</measure>
    <time_frame>From Dose 1 (at Day 0) until Month 12</time_frame>
    <description>MSCs are defined as AEs prompting emergency room or physician visits that are not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that are not related to common diseases. Common diseases include: upper respiratory infections sinusitis, pharyngitis, gastroenteritis, urinary tract infections and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Causally Related to Vaccination, in a Subset of Subjects</measure>
    <time_frame>From Dose 1 (at Day 0) until Month 12</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination.</measure>
    <time_frame>During the entire study period up to the Visit 5 (18.5 years of age)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With HPV-16 and HPV-18 Antibody Concentrations Equal to or Above the Cut-off Values, by Gender, in a Subset of Subjects.</measure>
    <time_frame>At the time of Visit 1 (at Day 0), Visit 4 (at Month 7) and Visit 5 (at 18.5 years of age)</time_frame>
    <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titres for Anti-HPV-16 and Anti-HPV-18 Antibodies, by Gender, in a Subset of Subjects.</measure>
    <time_frame>At the time of visits 1 and 4 (at Day 0 and Month 7) and at the time of Visit 5 (18.5 years of age)</time_frame>
    <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Pregnancies With Onset During the Study</measure>
    <time_frame>Between Visit 1 (at Day 0) and Visit 5 (at 18.5 years of age)</time_frame>
    <description>Pregnancies with onset during the study were classified by their outcome. Outcomes included live infant with no apparent congenital anomaly, elective termination with no apparent congenital anomaly, spontaneous abortion with no apparent congenital anomaly, ectopic pregnancy, stillbirth with no apparent congenital anomaly and molar pregnancy. One additional pregnant subject was lost to follow-up during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Female Subjects With New Onset of Autoimmune Diseases (NOADs).</measure>
    <time_frame>Between Visit 1 (at Day 0) and Visit 5 (at 18.5 years of age)</time_frame>
    <description>NOADs include colitis ulcerative, juvenile arthritis, type 1 diabetes mellitus, coeliac disease and Chron's disease, Basedow's disease, erythema nodosum VIIth nerve paralysis and psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Female Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in a Female Subjects</measure>
    <time_frame>During the entire study period (from Dose 1-Day 0 to Visit 5-18.5 years of age)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Male Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in All Male Subjects</measure>
    <time_frame>During the entire study period (from dose1-Day 0 to Visit 5-18.5 years of age)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34206</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix/Engerix-B A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90% of male and female adolescents will receive GSK Biologicals' HPV Vaccine GSK580299. Rest of the subjects will receive Engerix-B™ vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix/Engerix-B B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90% of the female adolescents will receive GSK Biologicals' HPV Vaccine GSK580299. Male adolescents and rest of the female adolescents will receive Engerix-B™ vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All adolescents will receive Engerix-B™ vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' HPV Vaccine GSK580299</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Cervarix/Engerix-B A Group</arm_group_label>
    <arm_group_label>Cervarix/Engerix-B B Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B™</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Cervarix/Engerix-B A Group</arm_group_label>
    <arm_group_label>Cervarix/Engerix-B B Group</arm_group_label>
    <arm_group_label>Engerix-B Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study participants who the investigator or delegate believes that they and/or their
             parents/legally acceptable representative can and will comply with the requirements of
             the protocol (e.g. completion of the diary cards, return for follow-up visits) should
             be enrolled in the study.

          -  A male or female between, and including, 12 and 15 years of age at the time of the
             first vaccination.

        A written informed assent must be obtained from all study participants prior to enrolment.
        In addition, a written informed consent must be obtained from the study participants'
        parent or legally acceptable representative.

        Note: As according to the Finnish law legal age of consent is 15 years, a written informed
        consent form can be obtained from study participants aged 15 years old and their
        parent(s)/legally acceptable representative(s) will receive a letter informing them of
        their child participation to the study.

          -  Healthy male and female study participants as established by medical history before
             entering into the study. If needed, a history-directed clinical examination will be
             performed by the investigator or delegate (e.g. study nurse).

          -  Study participants must not be pregnant. Absence of pregnancy should be verified (e.g.
             urine pregnancy test) as per investigator's or delegate's clinical judgement.

          -  If the study participant is female, she must be of non-childbearing potential, i.e. be
             abstinent, have a current tubal ligation, hysterectomy, ovariectomy or be
             post-menopausal or pre-menarcheal, or if she is of childbearing potential, she must
             use adequate contraception for 30 days prior to vaccination and continue for 2 months
             after completion of the vaccination series.

        Exclusion Criteria:

          -  Previous vaccination against HPV or Hepatitis B virus.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Acute disease at the time of enrolment. (Acute disease is defined as the presence of a
             moderate or severe illness with or without fever. All vaccines can be administered to
             persons with a minor illness such as diarrhoea, mild upper respiratory infection with
             or without low-grade febrile illness, i.e. Oral temperature &lt;37.5°C (99.5°F) /
             Axillary temperature &lt;37.5°C (99.5°F) / Rectal temperature &lt;38°C (100.4°F).)

          -  Pregnant or lactating female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rauma</city>
        <zip>26100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>December 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2016</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccine</keyword>
  <keyword>Healthy adolescents</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Cervarix</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106636</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Immunisation phase (Visit 1 at Day 0 to Phone contact at Month 12) = adolescents (birth cohorts 1992-95) were vaccinated with Cervarix™ or Engerix™-B vaccine.
Effectiveness evaluation phase (Visit 5) = the impact of the vaccine intervention was assessed on female subjects of approximately 18.5 years of age.</recruitment_details>
      <pre_assignment_details>At study start, Cervarix™ vaccine was not licensed for use in boys so male subjects receiving the vaccine were considered as part of a Phase III trial. Although 34206 subjects were enrolled, only 32175 subjects were vaccinated and started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Pooled Group</title>
          <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Engerix-B Pooled Group</title>
          <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14837"/>
                <participants group_id="P2" count="17338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8346"/>
                <participants group_id="P2" count="5547"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6491"/>
                <participants group_id="P2" count="11791"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4793"/>
                <participants group_id="P2" count="10875"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Already received HPV vaccine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Urticaria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Blinded treatment broken</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mentally disabled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ICF not returned</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unable to read</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received without ICF</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Rejected origin of signature</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused participation to study</title>
              <participants_list>
                <participants group_id="P1" count="1665"/>
                <participants group_id="P2" count="883"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Pooled Group</title>
          <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Engerix-B Pooled Group</title>
          <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14837"/>
            <count group_id="B2" value="17338"/>
            <count group_id="B3" value="32175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="0.75"/>
                    <measurement group_id="B2" value="14.1" spread="0.76"/>
                    <measurement group_id="B3" value="14.1" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12399"/>
                    <measurement group_id="B2" value="8119"/>
                    <measurement group_id="B3" value="20518"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2438"/>
                    <measurement group_id="B2" value="9219"/>
                    <measurement group_id="B3" value="11657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Female Subjects With Vaccine Overall Effectiveness Against Genital Infection With Human Papilloma Virus (HPV) 16/18 Serotypes</title>
        <description>The analysis of overall effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in all subjects from the investigated group (prevalence rate in all subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
        <time_frame>At the time of visit 5 (at 18.5 years of age)</time_frame>
        <population>The analysis was based on the female study participants from the Total Enrolled cohort on effectiveness, which included all study participants who were previously enrolled in the immunization phase, and those who joined the trial at Visit 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix/Engerix-B A Group</title>
            <description>90% of male and female adolescents received Cervarix™ vaccine. Rest of the subjects received Engerix™-B vaccine. Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix/Engerix-B B Group</title>
            <description>90% of the female adolescents received Cervarix™ vaccine. Male adolescents and rest of the female adolescents received Engerix™-B vaccine. Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Engerix-B Group</title>
            <description>All adolescents were vaccinated with Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Subjects With Vaccine Overall Effectiveness Against Genital Infection With Human Papilloma Virus (HPV) 16/18 Serotypes</title>
          <description>The analysis of overall effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in all subjects from the investigated group (prevalence rate in all subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
          <population>The analysis was based on the female study participants from the Total Enrolled cohort on effectiveness, which included all study participants who were previously enrolled in the immunization phase, and those who joined the trial at Visit 5.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3629"/>
                <count group_id="O2" value="4029"/>
                <count group_id="O3" value="3168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis of overall effectiveness of GSK’s HPV-16/18 vaccine against HPV-16/18 genital infection in Arm A versus Arm C was based on stratified Mantel-Haenszel adjusted for clustering.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>1-Odds Ratio</param_type>
            <param_value>23.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.0</ci_lower_limit>
            <ci_upper_limit>51.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis of overall effectiveness of GSK’s HPV-16/18 vaccine against HPV-16/18 genital infection in Arm A versus Arm C was based on stratified Mantel-Haenszel adjusted for clustering.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>1-Odds Ratio</param_type>
            <param_value>49.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.1</ci_lower_limit>
            <ci_upper_limit>68.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis of overall effectiveness of GSK’s HPV-16/18 vaccine against HPV-16/18 genital infection in Arm A versus Arm C was based on stratified Mantel-Haenszel adjusted for clustering.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>1-Odds Ratio</param_type>
            <param_value>-52.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-139.4</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Female Subjects With Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Serotypes</title>
        <description>The analysis of total effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in HPV vaccinated subjects from the investigated group (prevalence rate in HPV vaccinated subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
        <time_frame>At the time of visit 5 (at 18.5 years of age)</time_frame>
        <population>The analysis was based on the female study participants from the Total Enrolled cohort on effectiveness, which included all study participants who were previously enrolled in the immunization phase, and those who joined the trial at Visit 5.</population>
        <group_list>
          <group group_id="O1">
            <title>No-vaccine Group</title>
            <description>Subjects who were enrolled but not vaccinated.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix/Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™/Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Subjects With Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Serotypes</title>
          <description>The analysis of total effectiveness was based on stratified Mantel-Haenszel adjusted for clustering. The effectiveness was computed as 1- the prevalence odd ratio in HPV vaccinated subjects from the investigated group (prevalence rate in HPV vaccinated subjects from the investigated arm/prevalence rate in all subjects from Arm C).</description>
          <population>The analysis was based on the female study participants from the Total Enrolled cohort on effectiveness, which included all study participants who were previously enrolled in the immunization phase, and those who joined the trial at Visit 5.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3192"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms, in a Subset of Subjects.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
        <time_frame>Within 7 days (Days 0 - 6) after any vaccination</time_frame>
        <population>The analysis was based on the Total vaccinated cohort - the Diary card subset, which included a subset of male adolescents from Cervarix/Engerix-B and Engerix-B groups, who were selected for active assessment of safety using diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms, in a Subset of Subjects.</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
          <population>The analysis was based on the Total vaccinated cohort - the Diary card subset, which included a subset of male adolescents from Cervarix/Engerix-B and Engerix-B groups, who were selected for active assessment of safety using diary cards.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="603"/>
                <count group_id="O2" value="1028"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506" lower_limit="80.7" upper_limit="86.8"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="2.8" upper_limit="6.3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="24.5" upper_limit="31.8"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="18.5" upper_limit="25.2"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0.6" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Solicited General Symptoms, in a Subset of Subjects.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms, headache, myalgia, rash and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 7 days (Days 0 - 6) after any vaccination</time_frame>
        <population>The analysis was based on the Total vaccinated cohort - the Diary card subset, which included a subset of male adolescents from Cervarix/Engerix-B and Engerix-B groups, who were selected for active assessment of safety using diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Solicited General Symptoms, in a Subset of Subjects.</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms, headache, myalgia, rash and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total vaccinated cohort - the Diary card subset, which included a subset of male adolescents from Cervarix/Engerix-B and Engerix-B groups, who were selected for active assessment of safety using diary cards.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="1028"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Unsolicited Adverse Events (AEs), in a Subset of Subjects.</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 30 days (Days 0 - 29) after any vaccination</time_frame>
        <population>This analysis was based on the Total Vaccinated Cohort - the Diary Card subset - a subset of male adolescents from Cervarix/Engerix-B A and Engerix-B Groups selected for active assessment of safety using diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related to Vaccination Unsolicited Adverse Events (AEs), in a Subset of Subjects.</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>This analysis was based on the Total Vaccinated Cohort - the Diary Card subset - a subset of male adolescents from Cervarix/Engerix-B A and Engerix-B Groups selected for active assessment of safety using diary cards.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="643"/>
                <count group_id="O2" value="1047"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Rash and Urticaria, in a Subset of Subjects.</title>
        <time_frame>Within 30 minutes following vaccination</time_frame>
        <population>This analysis was based on the Total Vaccinated Cohort - the Diary Card subset - a subset of male adolescents from Cervarix/Engerix-B A and Engerix-B Groups selected for active assessment of safety using diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Rash and Urticaria, in a Subset of Subjects.</title>
          <population>This analysis was based on the Total Vaccinated Cohort - the Diary Card subset - a subset of male adolescents from Cervarix/Engerix-B A and Engerix-B Groups selected for active assessment of safety using diary cards.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="643"/>
                <count group_id="O2" value="1047"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed after Dose 1 (n=643, 1047)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infirmed after Dose 1 (n=643, 1047)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="643"/>
                    <measurement group_id="O2" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed after Dose 2 (n=634, 1042)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infirmed after Dose 2 (n=634, 1042)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634"/>
                    <measurement group_id="O2" value="1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed after Dose 3 (n=631, 1039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infirmed after Dose 3 (n=631,1039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="1039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Confirmed after Dose 3 (n=631, 1039)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects.</title>
        <description>MSCs are defined as AEs prompting emergency room or physician visits that are not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that are not related to common diseases. Common diseases include: upper respiratory infections sinusitis, pharyngitis, gastroenteritis, urinary tract infections and injury.</description>
        <time_frame>From Dose 1 (at Day 0) until Month 12</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort - Diary Card subset - a subset of male adolescents from the Cervarix/Engerix-B and Engerix-B Groups, selected for active assessment of safety using diary cards.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects.</title>
          <description>MSCs are defined as AEs prompting emergency room or physician visits that are not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that are not related to common diseases. Common diseases include: upper respiratory infections sinusitis, pharyngitis, gastroenteritis, urinary tract infections and injury.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort - Diary Card subset - a subset of male adolescents from the Cervarix/Engerix-B and Engerix-B Groups, selected for active assessment of safety using diary cards.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="643"/>
                <count group_id="O2" value="1047"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Causally Related to Vaccination, in a Subset of Subjects</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Dose 1 (at Day 0) until Month 12</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort subset of Male subjects with active follow-up Month 0-Month 12 for SAEs, which included the male subjects in the Diary Card subset and the remaining Cervarix/Engerix-B Group male subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Causally Related to Vaccination, in a Subset of Subjects</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was based on the Total Vaccinated Cohort subset of Male subjects with active follow-up Month 0-Month 12 for SAEs, which included the male subjects in the Diary Card subset and the remaining Cervarix/Engerix-B Group male subjects.</population>
          <units>Number</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2436"/>
                <count group_id="O2" value="1267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAEs assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination.</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period up to the Visit 5 (18.5 years of age)</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination.</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14837"/>
                <count group_id="O2" value="17338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With HPV-16 and HPV-18 Antibody Concentrations Equal to or Above the Cut-off Values, by Gender, in a Subset of Subjects.</title>
        <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
        <time_frame>At the time of Visit 1 (at Day 0), Visit 4 (at Month 7) and Visit 5 (at 18.5 years of age)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. Subjects who acquired either HPV-16 or HPV-18 infection during the trial were excluded from the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HPV-16 and HPV-18 Antibody Concentrations Equal to or Above the Cut-off Values, by Gender, in a Subset of Subjects.</title>
          <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. Subjects who acquired either HPV-16 or HPV-18 infection during the trial were excluded from the ATP cohort for immunogenicity.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL males [Day 0] (N=536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL males [Month 7] (N=536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL females [Day 0] (N=1163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL females [Month 7] (N=1163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL males [Day 0] (N=535)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL males [Month 7] (N=535)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL females [Day 0] (N=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL females [Month 7] (N=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=19 EL.U/mL males [18.5Y] (N=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=19 EL.U/mL females [18.5Y] (N=688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=18 EL.U/mL males [18.5Y] (N=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=18 EL.U/mL females [18.5Y] (N=686)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titres for Anti-HPV-16 and Anti-HPV-18 Antibodies, by Gender, in a Subset of Subjects.</title>
        <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
        <time_frame>At the time of visits 1 and 4 (at Day 0 and Month 7) and at the time of Visit 5 (18.5 years of age)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. Subjects who acquired either HPV-16 or HPV-18 infection during the trial were excluded from the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Titres for Anti-HPV-16 and Anti-HPV-18 Antibodies, by Gender, in a Subset of Subjects.</title>
          <description>The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off of the assay was 8 ELISA units per millilitre (EL.U/mL) for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18 at Visits 1 and 4 and 19 EL.U/mL for HPV-16 and 18 EL.U/mL for HPV-18 at Visit 5. The Immunogenicity subset comprised the male study participants from the Cervarix/Engerix-B A Group plus female study participants from the same Cervarix/Engerix-B A Group.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. Subjects who acquired either HPV-16 or HPV-18 infection during the trial were excluded from the ATP cohort for immunogenicity.</population>
          <units>Titres</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL males [Day 0] (N=536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.3" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL males [Month 7] (N=536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23959.1" lower_limit="22301.0" upper_limit="25740.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL females [Day 0] (N=1163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.4" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=8 EL.U/mL females [Month 7] (N=1163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21327.2" lower_limit="20338.9" upper_limit="22363.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL males [Day 0] (N=535)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL males [Month 7] (N=535)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8583.9" lower_limit="7974.7" upper_limit="9239.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL females [Day 0] (N=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.8" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=7 EL.U/mL females [Month 7] (N=1160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8227.3" lower_limit="7847.7" upper_limit="8625.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=19 EL.U/mL males [18.5Y] (N=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2759.5" lower_limit="2432.1" upper_limit="3130.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-16 &gt;=19 EL.U/mL females [18.5Y] (N=688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2609.6" lower_limit="2444.4" upper_limit="2785.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=18 EL.U/mL males [18.5Y] (N=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837.7" lower_limit="727.3" upper_limit="964.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 &gt;=18 EL.U/mL females [18.5Y] (N=686)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="890.0" lower_limit="826.2" upper_limit="958.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Pregnancies With Onset During the Study</title>
        <description>Pregnancies with onset during the study were classified by their outcome. Outcomes included live infant with no apparent congenital anomaly, elective termination with no apparent congenital anomaly, spontaneous abortion with no apparent congenital anomaly, ectopic pregnancy, stillbirth with no apparent congenital anomaly and molar pregnancy. One additional pregnant subject was lost to follow-up during the study.</description>
        <time_frame>Between Visit 1 (at Day 0) and Visit 5 (at 18.5 years of age)</time_frame>
        <population>The analysis was based on the total number of pregnant subjects reported, part of the Total Vaccinated cohort, which all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Pregnancies With Onset During the Study</title>
          <description>Pregnancies with onset during the study were classified by their outcome. Outcomes included live infant with no apparent congenital anomaly, elective termination with no apparent congenital anomaly, spontaneous abortion with no apparent congenital anomaly, ectopic pregnancy, stillbirth with no apparent congenital anomaly and molar pregnancy. One additional pregnant subject was lost to follow-up during the study.</description>
          <population>The analysis was based on the total number of pregnant subjects reported, part of the Total Vaccinated cohort, which all vaccinated subjects for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="728"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Live infant no apparent anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elective termination no apparent anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ectopic pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous abortion np apparent anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stillbirth no apparent congenital anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molar pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Female Subjects With New Onset of Autoimmune Diseases (NOADs).</title>
        <description>NOADs include colitis ulcerative, juvenile arthritis, type 1 diabetes mellitus, coeliac disease and Chron's disease, Basedow's disease, erythema nodosum VIIth nerve paralysis and psoriasis.</description>
        <time_frame>Between Visit 1 (at Day 0) and Visit 5 (at 18.5 years of age)</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Subjects With New Onset of Autoimmune Diseases (NOADs).</title>
          <description>NOADs include colitis ulcerative, juvenile arthritis, type 1 diabetes mellitus, coeliac disease and Chron's disease, Basedow's disease, erythema nodosum VIIth nerve paralysis and psoriasis.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14837"/>
                <count group_id="O2" value="17338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="54.8" lower_limit="43.5"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Female Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in a Female Subjects</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (from Dose 1-Day 0 to Visit 5-18.5 years of age)</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in a Female Subjects</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12399"/>
                <count group_id="O2" value="8119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Male Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in All Male Subjects</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (from dose1-Day 0 to Visit 5-18.5 years of age)</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Pooled Group</title>
            <description>Male subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B Pooled Group</title>
            <description>Male subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Male Subjects Reporting Any SAEs That Are Causally Related to Vaccination, in All Male Subjects</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2438"/>
                <count group_id="O2" value="9219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: up to Day 7 post vaccination. AEs: up to Day 30 post vaccination. SAEs up to Visit 5 at Month 96</time_frame>
      <desc>Adverse Events were collected in the Total Vaccinated Cohort Diary Card subset (TVC-DcS = a subset of males from Cervarix/Engerix-B and Engerix-B groups selected for active safety assessment using diary cards). SAEs were collected in the TVC-DcS and remaining Cervarix/Engerix-B Group male subjects. Related SAEs were collected from the TVC.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Pooled Group</title>
          <description>Male and female subjects receiving Cervarix™ vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Engerix-B Pooled Group</title>
          <description>Male and female subjects receiving Engerix™-B vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Traumatic renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Juvenile arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Astrocytoma, low grade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Disturbance in social behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Emotional disorder of childhood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="506" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="411" subjects_at_risk="1047"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="506" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="291" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="411" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Fever (Axilarry)</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="371" subjects_at_risk="1047"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="1047"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1047"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

